Europe’s leading biotech industry event

7-9 October 2008 · Exhibition Grounds, 30521 Hannover, Germany

BIOTECHNICA in Hannover is the leading event within the European biotech industry. It embraces every segment of biotechnology – from basic biotechnology and equipment, bio-informatics and services to the five major areas of application:

• Pharmaceuticals/medicine
• Industry
• Food
• Agriculture
• Chemical industry and the environment.

BIOTECHNICA has been organized by Deutsche Messe AG at the Hannover Exhibition Grounds since 1985.

Exhibition

The exhibition section of BIOTECHNICA charts the biotech industry’s value-adding chain from start to finish. From research and product development, via equipment, process technology and services to series production and marketing.

What’s more, all the German bio-regions and a large number of international bio-regions are represented at the show – making this an ideal showcase for smaller firms as well.

In this vibrant setting, where market leaders rub shoulders with newcomers, you’ll have every opportunity to get talking with business associates and customers – and of course to get down to business.

Conferences

The conference program of BIOTECHNICA 2008 is divided into the following themed segments:

• BioScience, featuring Germany’s foremost biotech congress, EUROPEAN BIOPERSPECTIVES, plus the “Science to Market” conference
• BioBusiness, featuring the revamped BIOTECHNICA PARTNERING initiative, the BIOTECHNICA INNOVATIONS FORUM (now located right on the exhibition floor in Hall 9)
• BioPolitics, featuring a rich conference program including two very high-caliber events being staged in collaboration with the European Commission and the European Parliament: The Biopolitics Conference (formerly “Deutsche Biotechnologietage”) will get the program rolling on day on of BIOTECHNICA

At the Convention Center and in the exhibition halls, more than 400 top-flight speakers will be talking about current trends and research findings, as well as successful practical applications.

Some of the leading industry personnel giving keynote welcomes and lectures include:

• Prof. Michael C. Flickinger, North Carolina State University, Raleigh, NC/USA
• Dr. Stephen Minger, King‘s College London/UK
• Prof. John Mattick, The University of Queensland, Brisbane/AUS
• Prof. Romas Kazlauskas, University of Minnesota, St. Paul, MN/USA

European Biotechnica Award

Deutsche Messe announces the EUROPEAN BIOTECHNICA AWARD at BIOTECHNICA 2008 for the sixth time. Together with its partners, Deutsche Messe invited European enterprises in the fields of biotechnology and life sciences to apply for this highly recognised award.

The total prize value amounts to EUR 100,000. The winning company will receive EUR 20,000 in cash, while further (non-monetary) prizes with a total value of EUR 80,000 will be awarded to all three finalists.

The award ceremony will take place during the opening ceremony of BIOTECHNICA on 6 October 2008 in Hannover, Germany.

Congratulations to the three finalists, which have been nominated by an independent international jury consisting of eleven members. The three finalists are:

Astex Therapeutics

Astex is a UK-based biotechnology company that discovers and develops novel small molecule therapeutics. Using its pioneering fragment-based drug discovery platform PyramidTM, Astex has built a pipeline of five molecularly-targeted oncology drugs, of which three are currently being tested in clinical trials and two are in pre-clinical development. In addition to its proprietary research programmes, Astex’s productivity in lead discovery has been endorsed through numerous partnerships with major pharmaceutical companies, including Novartis, AstraZeneca, Bayer-Schering, Boehringer Ingelheim and Johnson and Johnson. For further information please visit www.astex-therapeutics.com

GENEART

GENEART has developed into the world’s leading manufacturer of synthetic genes ever since entering the market in the year 2000. Today, GENEART AG is one of the foremost global specialists in the area of synthetic biology. The company contributes the key technologies necessary to develop and produce new therapeutics and vaccines. Furthermore GENEART customers rely on the company to improve enzymes, such as the ones used as additives in detergents, and to construct genetically altered bacteria, which produce complex biopolymers or degrade polymers, such as plastic or petroleum for example. For further information please visit www.geneart.com

immatics

immatics is a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics. immatics’ proprietary technology for the identification of tumor-associated peptides (TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing two multi-TUMAP products in clinical phase II studies – IMA901 for the treatment of renal cell carcinoma (RCC) and IMA910 for the treatment of colorectal carcinoma (CRC). Further product candidates are currently in pre-clinical development. immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Prof. Hans-Georg Rammensee) and is based in Tuebingen and in Munich, both in Germany. For further information please visit www.immatics.com

Please visit www.biotechnica.de for more information